LeMaitre Vascular Future Growth

Future criteria checks 1/6

LeMaitre Vascular is forecast to grow earnings and revenue by 14% and 7.1% per annum respectively. EPS is expected to grow by 13% per annum. Return on equity is forecast to be 11.9% in 3 years.

Key information

14.0%

Earnings growth rate

13.0%

EPS growth rate

Medical Equipment earnings growth	16.3%
Revenue growth rate	7.1%
Future return on equity	11.9%
Analyst coverage	Good
Last updated	25 Apr 2024

Recent future growth updates

Recent updates

Returns On Capital At LeMaitre Vascular (NASDAQ:LMAT) Paint A Concerning Picture

Oct 27

Is It Too Late To Consider Buying LeMaitre Vascular, Inc. (NASDAQ:LMAT)?

Oct 11

Does LeMaitre Vascular (NASDAQ:LMAT) Deserve A Spot On Your Watchlist?

Aug 30

The Returns On Capital At LeMaitre Vascular (NASDAQ:LMAT) Don't Inspire Confidence

Jul 06

Is LeMaitre Vascular, Inc. (NASDAQ:LMAT) Worth US$62.3 Based On Its Intrinsic Value?

May 20

Should You Think About Buying LeMaitre Vascular, Inc. (NASDAQ:LMAT) Now?

Mar 12

Should You Think About Buying LeMaitre Vascular, Inc. (NASDAQ:LMAT) Now?

Oct 23

Calculating The Fair Value Of LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Oct 05

LeMaitre Vascular (NASDAQ:LMAT) Could Be Struggling To Allocate Capital

Sep 13

LeMaitre Vascular: Reiterate Buy Thesis Following Strong Q2 Numbers

Sep 08

LeMaitre Vascular goes ex dividend tomorrow

Aug 23

LeMaitre Vascular: 16% Return Objective From Idiosyncratic Risk Premia

Jun 24

What Does LeMaitre Vascular, Inc.'s (NASDAQ:LMAT) Share Price Indicate?

Jun 15

Are Investors Undervaluing LeMaitre Vascular, Inc. (NASDAQ:LMAT) By 40%?

May 06

LeMaitre Vascular: Steady As She Goes

Apr 07

With EPS Growth And More, LeMaitre Vascular (NASDAQ:LMAT) Is Interesting

Apr 02

LeMaitre Vascular (NASDAQ:LMAT) Will Want To Turn Around Its Return Trends

Mar 15

Earnings and Revenue Growth Forecasts

NasdaqGM:LMAT - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	245	46	53	N/A	3
12/31/2025	227	42	45	47	7
12/31/2024	212	37	40	43	8
12/31/2023	193	30	29	37	N/A
9/30/2023	186	27	23	30	N/A
6/30/2023	177	25	19	26	N/A
3/31/2023	169	21	18	23	N/A
12/31/2022	162	21	22	25	N/A
9/30/2022	160	21	24	26	N/A
6/30/2022	160	22	29	33	N/A
3/31/2022	158	27	29	34	N/A
12/31/2021	154	27	30	35	N/A
9/30/2021	152	28	39	44	N/A
6/30/2021	151	29	40	44	N/A
3/31/2021	135	24	37	40	N/A
12/31/2020	129	21	32	35	N/A
9/30/2020	122	19	23	26	N/A
6/30/2020	115	16	13	17	N/A
3/31/2020	119	18	12	16	N/A
12/31/2019	117	18	10	14	N/A
9/30/2019	115	19	12	15	N/A
6/30/2019	111	18	12	15	N/A
3/31/2019	108	23	12	16	N/A
12/31/2018	106	23	16	20	N/A
9/30/2018	103	21	16	20	N/A
6/30/2018	104	22	18	24	N/A
3/31/2018	103	18	19	24	N/A
12/31/2017	101	17	16	23	N/A
9/30/2017	98	15	N/A	20	N/A
6/30/2017	96	14	N/A	18	N/A
3/31/2017	93	12	N/A	18	N/A
12/31/2016	89	11	N/A	17	N/A
9/30/2016	86	11	N/A	17	N/A
6/30/2016	82	9	N/A	14	N/A
3/31/2016	79	9	N/A	13	N/A
12/31/2015	78	8	N/A	11	N/A
9/30/2015	76	7	N/A	10	N/A
6/30/2015	74	6	N/A	9	N/A
3/31/2015	73	5	N/A	7	N/A
12/31/2014	70	4	N/A	6	N/A
9/30/2014	70	3	N/A	4	N/A
6/30/2014	67	3	N/A	4	N/A
3/31/2014	65	2	N/A	4	N/A
12/31/2013	64	3	N/A	5	N/A
9/30/2013	61	3	N/A	4	N/A
6/30/2013	59	3	N/A	4	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: LMAT's forecast earnings growth (14% per year) is above the savings rate (2.4%).

Earnings vs Market: LMAT's earnings (14% per year) are forecast to grow slower than the US market (14% per year).

High Growth Earnings: LMAT's earnings are forecast to grow, but not significantly.

Revenue vs Market: LMAT's revenue (7.1% per year) is forecast to grow slower than the US market (8.2% per year).

High Growth Revenue: LMAT's revenue (7.1% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: LMAT's Return on Equity is forecast to be low in 3 years time (11.9%).

LeMaitre Vascular Future Growth

Future criteria checks 1/6

Key information

Recent future growth updates

LeMaitre Vascular, Inc. Provides Earnings Guidance for the Second Quarter and Full Year 2024

Price target increased by 10% to US$71.29

LeMaitre Vascular, Inc. Provides Earnings Guidance for the First Quarter and Full Year 2024

LeMaitre Vascular, Inc. Provides Earnings Guidance for the Third Quarter Ending September 30, 2023, Fourth Quarter and Full Year Ending December 31, 2023

Price target increased by 9.0% to US$62.33

LeMaitre Vascular, Inc. Provides Earnings Guidance for the Second Quarter and Full Year of 2023

Recent updates

LeMaitre Vascular, Inc. Provides Earnings Guidance for the Second Quarter and Full Year 2024

LeMaitre Vascular, Inc.'s (NASDAQ:LMAT) Popularity With Investors Is Clear

LeMaitre Vascular, Inc. to Report Q1, 2024 Results on May 02, 2024

LeMaitre Vascular, Inc., Annual General Meeting, Jun 03, 2024

Is Now The Time To Put LeMaitre Vascular (NASDAQ:LMAT) On Your Watchlist?

Now 22% undervalued

Chairman & CEO exercised options to buy US$983k worth of stock.

Now 22% undervalued

Chairman & CEO recently sold US$6.9m worth of stock

Upcoming dividend of US$0.16 per share

Chairman & CEO notifies of intention to sell stock

Fourth quarter dividend increased to US$0.16

Price target increased by 10% to US$71.29

LeMaitre Vascular, Inc. Provides Earnings Guidance for the First Quarter and Full Year 2024

Calculating The Fair Value Of LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Full year 2023 earnings: EPS exceeds analyst expectations

LeMaitre Vascular, Inc. (NasdaqGM:LMAT) announces an Equity Buyback for $50 million worth of its shares.

LeMaitre Vascular, Inc. to Report Q4, 2023 Results on Feb 27, 2024

What Does LeMaitre Vascular, Inc.'s (NASDAQ:LMAT) Share Price Indicate?

Chairman & CEO exercised options to buy US$961k worth of stock.

Chairman & CEO recently sold US$2.8m worth of stock

Chairman & CEO notifies of intention to sell stock

Independent Director exercised options to buy US$395k worth of stock.

Chairman & CEO exercised options to buy US$680k worth of stock.

Upcoming dividend of US$0.14 per share at 1.1% yield

Third quarter 2023 earnings: EPS exceeds analyst expectations

LeMaitre Vascular, Inc. Approves Quarterly Dividend, Payable on November 30, 2023

Returns On Capital At LeMaitre Vascular (NASDAQ:LMAT) Paint A Concerning Picture

LeMaitre Vascular, Inc. to Report Q3, 2023 Results on Nov 01, 2023

Investor sentiment deteriorates as stock falls 18%

Is It Too Late To Consider Buying LeMaitre Vascular, Inc. (NASDAQ:LMAT)?

Does LeMaitre Vascular (NASDAQ:LMAT) Deserve A Spot On Your Watchlist?

Upcoming dividend of US$0.14 per share at 1.0% yield

LeMaitre Vascular, Inc. Provides Earnings Guidance for the Third Quarter Ending September 30, 2023, Fourth Quarter and Full Year Ending December 31, 2023

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

LeMaitre Vascular, Inc. to Report Q2, 2023 Results on Aug 01, 2023

The Returns On Capital At LeMaitre Vascular (NASDAQ:LMAT) Don't Inspire Confidence

Independent Director notifies of intention to sell stock

Chairman & CEO recently sold US$445k worth of stock

Is LeMaitre Vascular, Inc. (NASDAQ:LMAT) Worth US$62.3 Based On Its Intrinsic Value?

Chairman & CEO notifies of intention to sell stock

President & Director recently sold US$555k worth of stock

Investor sentiment improves as stock rises 22%

Chairman & CEO notifies of intention to sell stock

Price target increased by 9.0% to US$62.33

LeMaitre Vascular, Inc. Provides Earnings Guidance for the Second Quarter and Full Year of 2023

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Insufficient new directors

Should You Think About Buying LeMaitre Vascular, Inc. (NASDAQ:LMAT) Now?

Senior Vice President of Operations notifies of intention to sell stock

President & Director exercised options and sold US$258k worth of stock

Upcoming dividend of US$0.14 per share at 1.1% yield

Full year 2022 earnings released: EPS: US$0.94 (vs US$1.27 in FY 2021)

LeMaitre Vascular, Inc. to Report Q4, 2022 Results on Feb 23, 2023

President & Director exercised options to buy US$145k worth of stock.

Chairman & CEO exercised options to buy US$584k worth of stock.

Chairman & CEO exercised options to buy US$546k worth of stock.

Upcoming dividend of US$0.13 per share

Investor sentiment deteriorated over the past week

LeMaitre Vascular, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year of 2022

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Should You Think About Buying LeMaitre Vascular, Inc. (NASDAQ:LMAT) Now?

LeMaitre Vascular, Inc. to Report Q3, 2022 Results on Oct 27, 2022

Calculating The Fair Value Of LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Lemaitre Vascular, Inc. Appoints Martha Shadan as Director

LeMaitre Vascular (NASDAQ:LMAT) Could Be Struggling To Allocate Capital

LeMaitre Vascular: Reiterate Buy Thesis Following Strong Q2 Numbers

LeMaitre Vascular goes ex dividend tomorrow

CFO, Treasurer exercised options and sold US$895k worth of stock